Product Description
For schizophrenia and parkinson's disease psychosis (Sourced from: https://www.sumitomo-pharma.com/rd/clinical/pipeline.html)
Mechanisms of Action: 5-HT1A Agonist,TAAR1 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: Sunovion
Clinical Description
Countries in Clinic: Bulgaria, China, Colombia, Croatia, Czech Republic, Estonia, Finland, Germany, Hungary, Japan, Latvia, Malaysia, Philippines, Poland, Romania, Russia, Serbia, Slovakia, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 24
Highest Development Phases
Phase 3: Depressive Disorder, Major|Generalized anxiety disorder|Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2071210003 | P3 |
Recruiting |
Schizophrenia |
2025-09-30 |
|
SEP361-226 | P3 |
Recruiting |
Generalized anxiety disorder |
2025-08-26 |
|
NCT05593029 | P3 |
Recruiting |
Depressive Disorder, Major |
2025-05-01 |
95% |
jRCT2031220039 | P3 |
Recruiting |
Schizophrenia |
2025-03-31 |